A process for producing crystalline form I of cabergoline, which process comprises the preparation of Form V using heptane as precipitation solvent, and its exclusive conversion into crystalline Form I of cabergoline. The present crystallization process from toluene-heptane solvent system for form V involves "reverse addition" of toluene-cabergoline concentrate to cold heptane.

 
Web www.patentalert.com

> Pharmaceutical Methods, Dosing Regimes And Dosage Forms For The Treatment Of Alzheimer's Disease

~ 00310